123 Results for "

CD3 T cell

" in MedChemExpress (MCE) Product Catalog:
Products (123)

123 Results for "CD3 T cell" in MCE Product Catalog:

3
Blinatumomab
Blinatumomab
0 Images
3 Cited Publications
Cat. No.: HY-P9963
CAS No.: 853426-35-4
Synonyms: bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO

Target:  

CD19

Research Areas:  

Cancer

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
2
Tarlatamab
Tarlatamab
0 Images
2 Cited Publications
Cat. No.: HY-P99575
CAS No.: 2307488-83-9
Synonyms: AMG-757

Target:  

Notch

Research Areas:  

Inflammation/Immunology Cancer

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
2
Epcoritamab
Epcoritamab
0 Images
2 Cited Publications
Cat. No.: HY-P99931
CAS No.: 2134641-34-0
Synonyms: GEN3013

Target:  

CD3 CD20

Research Areas:  

Cancer

Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
2
Cibisatamab
Cibisatamab
0 Images
2 Cited Publications
Cat. No.: HY-P99011
CAS No.: 1855925-27-7

Target:  

CD3

Research Areas:  

Cancer

Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
1
Mosunetuzumab
Mosunetuzumab
0 Images
1 Cited Publications
Cat. No.: HY-P99033
CAS No.: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816

Target:  

CD20 CD3

Research Areas:  

Inflammation/Immunology Cancer

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
1
Glofitamab
Glofitamab
0 Images
1 Cited Publications
Cat. No.: HY-P99024
CAS No.: 2229047-91-8
Synonyms: RO7082859; RG-6026

Target:  

CD20 CD3

Research Areas:  

Inflammation/Immunology Cancer

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
1
Pasotuxizumab
Pasotuxizumab
0 Images
1 Cited Publications
Cat. No.: HY-P99802
CAS No.: 1442657-12-6
Synonyms: BAY 2010112; AMG 212; MT112

Target:  

CD3

Research Areas:  

Cancer

Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
1
Obrindatamab
Obrindatamab
0 Images
1 Cited Publications
Cat. No.: HY-P99762
CAS No.: 2069959-72-2
Synonyms: MGD009

Target:  

CD3

Research Areas:  

Cancer

Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
1
Gresonitamab
Gresonitamab
0 Images
1 Cited Publications
Cat. No.: HY-P99350
CAS No.: 2413817-97-5
Synonyms: AMG 910; Anti-Human CD3xClaudin18 2

Target:  

CD3

Research Areas:  

Cancer

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
1
Anti-Mouse CD3 Antibody (17A2)
Anti-Mouse CD3 Antibody (17A2)
0 Images
1 Cited Publications
Cat. No.: HY-P99124

Target:  

CD3

Research Areas:  

Inflammation/Immunology

Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .
1
Pavurutamab
Pavurutamab
0 Images
1 Cited Publications
Cat. No.: HY-P99814
CAS No.: 2250292-39-6
Synonyms: AMG-701

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
1
Human CD3/CD28 T Cell Activation Magnetic Beads
Human CD3/CD28 T Cell Activation Magnetic Beads
0 Images
1 Cited Publications
Cat. No.: HY-K0353

MCE Human CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation.

1
CD3 epsilon Antibody (YA542)
CD3 epsilon Antibody (YA542)
0 Images
1 Cited Publications
Cat. No.: HY-P80598
Synonyms: CD3E; T3E; T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e

Host:  

Rabbit

Application:  

WB, IHC-P, IP

Reactivity:  

Human

1
CD3 epsilon Antibody (YA6497)
CD3 epsilon Antibody (YA6497)
0 Images
1 Cited Publications
Cat. No.: HY-P86804
Synonyms: 4930549J05Rik antibody; A430104F18Rik antibody; AW552088 antibody; CD247 antibody; CD3 antibody; CD3 delta antibody; CD3 epsilon antibody; CD3 eta antibody; CD3 gamma antibody; CD3 zeta antibody; CD3H antibody; CD3Q antibody; CD3Z antibody; CD3zeta antibody; Ctg3 antibody; FLJ17620 antibody; FLJ17664 antibody; FLJ18683 antibody; FLJ79544 antibody FLJ94613 antibody; IMD19 antibody; Leu-4 antibody; MGC138597 antibody; OKT3, delta chain antibody; OTTHUMP00000032544 antibody; T cell receptor antibody; T3 antibody; T3d antibody; T3e antibody; T3g antibody; T3z antibody; TCRE antibody; TCRk antibody; Tcrz antibody; TCRzeta antibody

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF, IP, IF-Tissue, mIHC

Reactivity:  

Human

1
Amlitelimab
Amlitelimab
0 Images
1 Cited Publications
Cat. No.: HY-P99434
CAS No.: 2378692-15-8
Synonyms: KY1005; SAR445229

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
Teclistamab
Teclistamab
0 Images
Cat. No.: HY-P99392
CAS No.: 2119595-80-9
Synonyms: JNJ-7957; JNJ-64007957; Tecvayli

Target:  

CD3

Research Areas:  

Cancer

Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
Cevostamab
Cevostamab
0 Images
Cat. No.: HY-P99601
CAS No.: 2249888-53-5
Synonyms: BFCR 4350A; RG 6160; RO 7187797

Target:  

CD3

Research Areas:  

Neurological Disease Cancer

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
Surovatamig
Surovatamig
0 Images
Cat. No.: HY-P991028
CAS No.: 2892667-02-4
Synonyms: AZD0486; TNB-486

Target:  

CD3 CD19 Interleukin Related TNF Receptor IFNAR

Research Areas:  

Cancer

Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .
Xaluritamig
Xaluritamig
0 Images
Cat. No.: HY-P990688
CAS No.: 2559056-68-5
Synonyms: AMG-509

Target:  

CD3

Research Areas:  

Cancer

Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
Anti-CD3 Antibody (OKT-3)
Anti-CD3 Antibody (OKT-3)
0 Images
Cat. No.: HY-P990864

Target:  

CD3

Research Areas:  

Inflammation/Immunology

Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human CD3. Anti-CD3 Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease .
Assay Types